Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Cell Host Microbe
; 28(3): 455-464.e2, 2020 09 09.
Article
in English
| MEDLINE | ID: covidwho-654072
ABSTRACT
Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Interferon-alpha
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Variants
Country/Region as subject:
Asia
Language:
English
Journal:
Cell Host Microbe
Journal subject:
Microbiology
Year:
2020
Document Type:
Article
Affiliation country:
J.chom.2020.07.005
Similar
MEDLINE
...
LILACS
LIS